Drugs / Allogeneic CD19/BCMA-targeted CAR-γδT cell
Allogeneic CD19/BCMA-targeted CAR-γδT cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07490275 | Jul 2026 → Dec 2028 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune thrombocytopenia, myositis disease, systemic lupus erythematosus +1 | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CD19/BCMA-targeted CAR-γδT cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07490275 ↗ |
| Action | Deplete | “Allogeneic CD19/BCMA-targeted CAR-γδT cell” NCT07490275 ↗ |
| Modality | Cell therapy | “Biological: Allogeneic CD19/BCMA-targeted CAR-γδT cell” NCT07490275 ↗ |